CLSD241220P5000
- 0.00
- 0.000.00%
Clearside Biomedical Newsroom
Clearside Biomedical Is Maintained at Buy by Chardan Capital
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations
JonesTrading Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Promising Outlook for Clearside Biomedical: Buy Rating Backed by Strong Phase 2b ODYSSEY Trial Data and Robust Cash Position
Oppenheimer Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $5
Needham Maintains Clearside Biomedical(CLSD.US) With Buy Rating, Maintains Target Price $6
Express News | Needham Reiterates Buy on Clearside Biomedical, Maintains $6 Price Target
Clearside Biomedical Analyst Ratings
Clearside Biomedical | 10-Q: Q3 2024 Earnings Report
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript Summary
Clearside Biomedical, Inc. (CLSD) Q3 2024 Earnings Conference Call Transcript
Express News | Clearside Biomedical Inc: Believes It Will Have Sufficient Resources to Fund Its Planned Operations Into Q3 of 2025
Clearside Biomedical | 8-K: Clearside Biomedical Announces Third Quarter 2024 Financial Results and Provides Corporate Update
Clearside Biomedical Q3 EPS $(0.10) Beats $(0.13) Estimate, Sales $1.04M Beat $122.86K Estimate
Express News | Clearside Biomedical Q3 Net Income USD -7.7 Million
Clearside Biomedical 3Q Loss/Shr 10c >CLSD
Here Are the Major Earnings After the Close Today
Even After Rising 13% This Past Week, Clearside Biomedical (NASDAQ:CLSD) Shareholders Are Still Down 77% Over the Past Three Years
Express News | Clearside Biomedical Inc - New Drug Applications for Arvn001 Under Review in Australia and Singapore
Express News | Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement With Santen Pharmaceutical Co., Ltd for Arvn001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema